Trial Profile

Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etoposide (Primary) ; Irinotecan (Primary) ; Isotretinoin (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Vincristine (Primary)
Indications Wilms' tumour
Focus Therapeutic Use
Acronyms MetroWILMS-1906

Most Recent Events

17 Jun 2024 New trial record
11 Jun 2024 According to an ORPHELIA Pharma media release, the company to collaborate with oscar lambret clinical center to study kizfizo, the first pediatric drinkable formulation of temozolomide in the MetroWILMS-1906 study. MetroWILMS is sponsored by the Oscar Lambret clinical center on behalf of the Societe Francaise des Cancers de l'Enfant (SFCE), Nephroblastoma committee. Helene Sudour-Bonnange is investigator in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com